Alector Inc (ALEC) Implied Volatility Current

Tracking ALEC implied volatility helps you identify when options premiums on Alector Inc are historically cheap or expensive, and where the best trades are hiding. Alector Inc implied volatility reflects the market's expectation of future price movement: when ALEC IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Alector Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For ALEC, tracking metrics like ALEC IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on ALEC signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where ALEC implied volatility sits today versus where it has been. Our scanner ranks Alector Inc implied volatility against its historical range, surfaces extremes in ALEC IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Alector Inc IV is rich or cheap — measure it, then act on it.